You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

~ Buy the LOKELMA (sodium zirconium cyclosilicate) Drug Profile, 2024 PDF Report in the Report Store ~

LOKELMA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lokelma patents expire, and what generic alternatives are available?

Lokelma is a drug marketed by Astrazeneca and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-two patent family members in thirty-five countries.

The generic ingredient in LOKELMA is sodium zirconium cyclosilicate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sodium zirconium cyclosilicate profile page.

DrugPatentWatch® Generic Entry Outlook for Lokelma

Lokelma was eligible for patent challenges on May 18, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 14, 2035. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LOKELMA?
  • What are the global sales for LOKELMA?
  • What is Average Wholesale Price for LOKELMA?
Drug patent expirations by year for LOKELMA
Drug Prices for LOKELMA

See drug prices for LOKELMA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LOKELMA
Generic Entry Date for LOKELMA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FOR SUSPENSION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LOKELMA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NephroNet, Inc.Phase 4
Michael FuPhase 2
St George's, University of LondonPhase 3

See all LOKELMA clinical trials

Paragraph IV (Patent) Challenges for LOKELMA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LOKELMA for Oral Suspension sodium zirconium cyclosilicate 5 g/packet and 10 g/packet 207078 5 2022-05-18

US Patents and Regulatory Information for LOKELMA

LOKELMA is protected by fourteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of LOKELMA is ⤷  Subscribe.

This potential generic entry date is based on patent ⤷  Subscribe.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-001 May 18, 2018 RX Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-002 May 18, 2018 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-002 May 18, 2018 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-001 May 18, 2018 RX Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-001 May 18, 2018 RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Astrazeneca LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-001 May 18, 2018 RX Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-002 May 18, 2018 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LOKELMA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-001 May 18, 2018 ⤷  Subscribe ⤷  Subscribe
Astrazeneca LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-002 May 18, 2018 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for LOKELMA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
AstraZeneca AB Lokelma sodium zirconium cyclosilicate EMEA/H/C/004029
Lokelma is indicated for the treatment of hyperkalaemia in adult patients.
Authorised no no no 2018-03-22
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for LOKELMA

When does loss-of-exclusivity occur for LOKELMA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 6369
Patent: USO PROLONGADO DE COMPOSICIONES DE SILICATO DE CIRCONIO Y MÉTODOS PARA SU USO
Estimated Expiration: ⤷  Subscribe

Australia

Patent: 16338753
Patent: Extended use zirconium silicate compositions and methods of use thereof
Estimated Expiration: ⤷  Subscribe

Brazil

Patent: 2018007189
Patent: composições de silicato de zircônio para uso prolongado e métodos de uso dos mesmos
Estimated Expiration: ⤷  Subscribe

Canada

Patent: 00950
Patent: COMPOSITIONS DE SILICATE DE ZIRCONIUM A USAGE PROLONGE ET PROCEDES D'UTILISATION CORRESPONDANTS (EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOF)
Estimated Expiration: ⤷  Subscribe

Chile

Patent: 18000916
Patent: Composiciones de silicato de zirconio de uso prolongado y métodos de uso de las mismas
Estimated Expiration: ⤷  Subscribe

China

Patent: 8137620
Patent: 扩大使用硅酸锆组合物及其使用方法 (EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOF)
Estimated Expiration: ⤷  Subscribe

Patent: 3143958
Patent: 扩大使用硅酸锆组合物及其使用方法 (Extended use zirconium silicate compositions and methods of use thereof)
Estimated Expiration: ⤷  Subscribe

Costa Rica

Patent: 180276
Patent: COMPOSICIONES DE SILICATO DE ZIRCONIO DE USO PROLONGADO Y MÉTODOS DE USO DE LAS MISMAS
Estimated Expiration: ⤷  Subscribe

Eurasian Patent Organization

Patent: 5890
Patent: КОМПОЗИЦИИ НА ОСНОВЕ СИЛИКАТА ЦИРКОНИЯ ДЛЯ ЛЕЧЕНИЯ ГИПЕРКАЛИЕМИИ (ZIRCONIUM SILICATE COMPOSITIONS FOR TREATING HYPERKALEMIA)
Estimated Expiration: ⤷  Subscribe

Patent: 1890875
Patent: КОМПОЗИЦИИ НА ОСНОВЕ СИЛИКАТА ЦИРКОНИЯ ДЛЯ ДЛИТЕЛЬНОГО ПРИМЕНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
Estimated Expiration: ⤷  Subscribe

Patent: 2091273
Patent: КОМПОЗИЦИИ НА ОСНОВЕ СИЛИКАТА ЦИРКОНИЯ ДЛЯ ДЛИТЕЛЬНОГО ПРИМЕНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
Estimated Expiration: ⤷  Subscribe

European Patent Office

Patent: 62456
Patent: COMPOSITIONS DE SILICATE DE ZIRCONIUM À USAGE PROLONGÉ ET PROCÉDÉS D'UTILISATION CORRESPONDANTS (EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOF)
Estimated Expiration: ⤷  Subscribe

Hong Kong

Patent: 54808
Patent: 長期使用的硅酸鋯組合物及其使用方法 (EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOF)
Estimated Expiration: ⤷  Subscribe

Israel

Patent: 8478
Patent: שימוש מורחב בתרכובות זירקוניום סיליקוניות ושיטות לשימושן (Extended use zirconium silicate compositions and methods of use thereof)
Estimated Expiration: ⤷  Subscribe

Japan

Patent: 46700
Estimated Expiration: ⤷  Subscribe

Patent: 18530596
Patent: ケイ酸ジルコニウム組成物の長期間の使用及びその使用方法
Estimated Expiration: ⤷  Subscribe

Malaysia

Patent: 7088
Patent: EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOF
Estimated Expiration: ⤷  Subscribe

Mexico

Patent: 18004440
Patent: COMPOSICIONES DE SILICATO DE ZIRCONIO DE USO PROLONGADO Y METODOS DE USO DE LAS MISMAS. (EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOF.)
Estimated Expiration: ⤷  Subscribe

Philippines

Patent: 018500786
Patent: EXTENDED USE ZIRCONIUM COMPOSITIONS AND METHODS OF USE THEREOF
Estimated Expiration: ⤷  Subscribe

South Africa

Patent: 1803095
Patent: EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOF
Estimated Expiration: ⤷  Subscribe

South Korea

Patent: 180067614
Patent: 연장된 용도의 지르코늄 실리케이트 조성물 및 이의 사용 방법
Estimated Expiration: ⤷  Subscribe

Taiwan

Patent: 42004
Estimated Expiration: ⤷  Subscribe

Patent: 1717972
Patent: Extended use zirconium silicate compositions and methods of use thereof
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LOKELMA around the world.

Country Patent Number Title Estimated Expiration
Canada 3000950 COMPOSITIONS DE SILICATE DE ZIRCONIUM A USAGE PROLONGE ET PROCEDES D'UTILISATION CORRESPONDANTS (EXTENDED USE ZIRCONIUM SILICATE COMPOSITIONS AND METHODS OF USE THEREOF) ⤷  Subscribe
Eurasian Patent Organization 035890 КОМПОЗИЦИИ НА ОСНОВЕ СИЛИКАТА ЦИРКОНИЯ ДЛЯ ЛЕЧЕНИЯ ГИПЕРКАЛИЕМИИ (ZIRCONIUM SILICATE COMPOSITIONS FOR TREATING HYPERKALEMIA) ⤷  Subscribe
Canada 2929978 ⤷  Subscribe
Israel 258478 שימוש מורחב בתרכובות זירקוניום סיליקוניות ושיטות לשימושן (Extended use zirconium silicate compositions and methods of use thereof) ⤷  Subscribe
Israel 237905 ⤷  Subscribe
China 106170283 用于治疗高钾血症的微孔硅酸锆 (Microporous zirconium silicate for the treatment of hyperkalemia) ⤷  Subscribe
South Africa 201502186 MICROPOROUS ZIRCONIUM SILICATE FOR TREATING HYPERKALEMIA ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LOKELMA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0290047 SPC/GB97/078 United Kingdom ⤷  Subscribe PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
2203431 15C0013 France ⤷  Subscribe PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
0480717 98C0022 France ⤷  Subscribe PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825
1499331 SPC/GB13/034 United Kingdom ⤷  Subscribe PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
0579826 SPC/GB02/042 United Kingdom ⤷  Subscribe PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422
1175904 2007C/048 Belgium ⤷  Subscribe PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826
2203431 2015/009 Ireland ⤷  Subscribe PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

LOKELMA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Lokelma

Introduction to Lokelma

Lokelma, also known as sodium zirconium cyclosilicate, is a potassium binder drug developed by AstraZeneca for the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. Since its approval in 2018, Lokelma has been a significant player in the hyperkalemia treatment market.

Market Overview

The hyperkalemia treatment market, in which Lokelma operates, is expected to experience robust growth. This market is projected to register a Compound Annual Growth Rate (CAGR) of 16.79% over the forecast period from 2024 to 2029. The increasing prevalence of hyperkalemia, particularly among the aging population and those with chronic kidney disease, drives this growth[1].

Regional Market Performance

North America, led by the United States, is anticipated to hold a significant share in the hyperkalemia treatment market. The region's growth is driven by factors such as increased healthcare expenditure, ongoing research and development, and the rising prevalence of hyperkalemia. The Asia-Pacific region, however, is expected to be the fastest-growing market over the forecast period[1].

Financial Performance of Lokelma

Revenue Growth

Lokelma has shown steady revenue growth since its approval. In 2022, the drug generated $289 million in annual sales. By the third quarter of 2023, this figure had increased to $300 million for the first nine months of the year. GlobalData predicts that worldwide sales of Lokelma will rise to $799 million by 2029[4].

Market Impact

Despite initial expectations that Lokelma would be a blockbuster drug, its sales have not yet reached those heights. However, the drug continues to gain traction, particularly in its approved indication for managing hyperkalemia in patients with chronic kidney disease (CKD) and heart failure.

Clinical Trials and Development

AstraZeneca has been conducting various clinical trials to expand the evidence base for Lokelma's use across different cardiorenal conditions. However, two Phase III "evidence" trials, STABILIZE-CKD and DIALIZE-Outcomes, were recently discontinued due to slow enrollment and low clinical event rates. This decision was not based on safety concerns and does not affect the drug's current approved indication[4].

Clinical Evidence and Value

Recent studies have highlighted the value of Lokelma in clinical practice. For instance, evidence presented in November 2023 indicated that Lokelma more than doubled the odds of patients with CKD or heart failure to maintain their ability to stay on lifesaving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy compared to those not on a potassium binder treatment[4].

Competitive Landscape

The hyperkalemia treatment market is relatively consolidated, with a few key players dominating the scene. AstraZeneca, along with other major companies like Sanofi SA, Perrigo Company PLC, CSL Limited (Vifor Pharma Management Ltd.), and Ardelyx, are among the leading players in this market[1].

Financial Trajectory of AstraZeneca

AstraZeneca's overall financial performance provides context for Lokelma's growth. In the first half of 2024, AstraZeneca reported an 18% increase in total revenue to $25,617 million, driven by an 18% increase in product sales and continued growth in alliance revenue from partnered medicines. The company's core product sales gross margin remained stable at 82%, and the core operating margin was 33%[2][5].

Future Outlook

Despite the discontinuation of the two Phase III trials, Lokelma's future outlook remains positive. The drug's established efficacy and the growing demand for hyperkalemia treatments are expected to drive its sales. AstraZeneca's continued investment in research and development, as well as its strong pipeline of potential new medicines, further supports the company's long-term growth strategy[3][4].

Key Takeaways

  • Revenue Growth: Lokelma's revenue has been increasing steadily, with predictions of reaching $799 million by 2029.
  • Clinical Evidence: The drug has shown significant clinical value, particularly in maintaining RAASi therapy in patients with CKD or heart failure.
  • Market Dynamics: The hyperkalemia treatment market is growing rapidly, driven by increasing prevalence and research focus.
  • Competitive Landscape: AstraZeneca is one of the key players in a relatively consolidated market.
  • Financial Performance: AstraZeneca's overall financial health supports the continued growth and development of Lokelma.

FAQs

What is the current market size of the hyperkalemia treatment market?

The hyperkalemia treatment market is projected to register a CAGR of 16.79% during the forecast period (2024-2029), with North America holding the largest market share[1].

Who are the major players in the hyperkalemia treatment market?

Key players include Sanofi SA, Perrigo Company PLC, CSL Limited (Vifor Pharma Management Ltd.), AstraZeneca, and Ardelyx[1].

What are the factors driving the growth of the hyperkalemia treatment market?

The market is driven by the increasing prevalence of hyperkalemia, rising focus on research and development, and increased healthcare expenditure, particularly in North America[1].

Why were the Phase III trials for Lokelma discontinued?

The trials were discontinued due to slow enrollment and low clinical event rates, but this decision was not based on safety concerns and does not affect the drug's current approved indication[4].

What is the predicted future revenue for Lokelma?

GlobalData predicts that worldwide sales of Lokelma will increase to $799 million by 2029[4].

Sources

  1. Mordor Intelligence: Hyperkalemia Treatment Market - Size, Share & Industry Analysis
  2. Business Wire: AstraZeneca's H1 and Q2 2024 Financial Results
  3. AstraZeneca: Full year and Q4 2022 results | AstraZeneca
  4. BioSpace: AstraZeneca Axes Two Phase III Hyperkalemia Trials for Lokelma
  5. AstraZeneca: H1 and Q2 2024 results Strong Financial Performance and Pipeline Progress

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.